Abstract
We previously showed that variant SLCO1B1 haplotype *1b (A388G) accelerates and that *5 (T521C) delays hepatocellular uptake of the HMG-CoA reductase inhibitor pravastatin [Mwinyi et al. (2004): Clin Pharmacol Ther 75:415–421]. In the present study we checked for differential effects of variant SLCO1B1 haplotypes on hepatocellular cholesterol synthesis. We analyzed the serum levels of cholesterol, lathosterol, and campesterol in healthy white males which had been grouped on the basis of their SLCO1B1 haplotype: *1a (n=10), *1b (n=10), and *5 (n=8). The subjects received a single oral dose of 40 mg pravastatin. Cholesterol and lathosterol levels were lower in all subjects following pravastatin intake for up to 24. Median levels 6 h post-dosing of lathosterol decreased in each SLCO1B1 haplotype group in the rank order of *1b (−0.11 mg dl–1; min–max: −0.20 to −0.04; p=0.005) > *1a (−0.09 mg dl–1; min–max: −0.22 to −0.05; p=0.005) > *5 (−0.07 mg dl–1; min–max: −0.17 to −0.05; p=0.012). Lathosterol median-change values were significantly greater in haplotype *1b than in haplotype *5 individuals (p=0.041, non-adjusted), which was congruent with the extent of mean changes in lathosterol-to-cholesterol ratios, although the latter did not reach statistical significance. Post-treatment serum levels of campesterol were not affected by SLCO1B1 haplotype. Interestingly, sterol basal serum levels tended to be highest in *1b carriers, followed by those in *1a and *5 individuals, with significant differences in lathosterol concentrations between the *1b and *5 (p=0.041, non-adjusted) haplotype group. Our findings suggest an association of SLCO1B1*1b and *5 haplotypes to pravastatin’s inhibition of the hepatocellular HMG-CoA reductase. Furthermore, SLCO1B1 haplotypes seem to play a role in basal cholesterol homeostasis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chiang JYL (1998) Regulation of bile acid synthesis. Front Biosci 3:D176–D193
Fuchs M (2003) Bile acid regulation of hepatic physiology: III. Regulation of bile acid synthesis: past progress and future challenges. Am J Physiol Gastrointest Liver Physiol 284:G551–G557
Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, Kliewer SA (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6:517–526
Gupta S, Pandak WM, Hylemon PB (2002) LXR alpha is the dominant regulator of CYP7A1 transcription. Biochem Biophys Res Commun 293:228–243
Hagenbuch B, Meier PJ (1996) Sinusoidal (basolateral) bile salt uptake systems of hepatocytes. Semin Liver Dis 16:129–136
Hatanaka T (2000) Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet 39:397–412
Hofmann AF (1999) The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 159:2647–2658
Ishizuka H, Konno K, Naganuma H, Nishimura K, Kouzuki H, Suzuki H, Sugiyama Y (1998) Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. J Pharmacol Exp Ther 287:37–42
Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B (2001) Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120:525–533
Marzolini C, Tirona RG, Kim RB (2004) Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 5:273–282
Michalski C, Cui Y, Nies AT, Nuessler AK, Neuhaus P, Zanger UM, Klein K, Eichelbaum M, Keppler D, Konig J (2002) A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem 277:43058–43063
Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T (2004) Evidence for inverse effects of OATP1B1 (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 75:415–421
Myant NB, Mitropoulos KA (1977) Cholesterol 7α-hydroxylase. J Lipid Res 18:135–153
Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T, Nishimura K (2001) Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 297:861–867
Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivisto KT (2004) High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP1B1, SLCO1B1). Pharmacogenetics 14:429–440
Niemi M, Neuvonen PJ, Hofmann U, Backmann JT, Schwab M, Lutjohann D, von Bergmann K, Eichelbaum M, Kivisto KT (2005) Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenetics and Genomics 15:303–309
Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K, Sugiyama Y (2003) Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554–65
Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A, Yokoi T (2002) Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allelic frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 302:804–13
Schroepfer JG (2000) Oxysterols: modulators of cholesterol metabolism and other processes. Physiol Rev 80:361–554
Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K (2002) Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106:1943–1948
Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J, Tokunaga K, Kondo I, Sugiyama Y, Miki T (2004) Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 19:375–380
Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A (2001) Functional characterization of human organic anion transporting polypeptide B (OATP1B1) in comparison with liver-specific OATP1B1. Pharm Res 18:1262–1269
Tamasawa N, Hayakari M, Murakami H, Matsui J, Suda T (1997) Reduction of oxysterol levels up-regulates HMG-CoA reductase activity in rat liver. Atherosclerosis 131:237–242
Tirona RG, Leake BF, Merino G, Kim RB (2001) Polymorphisms in OATP1B1: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 276:35669–35675
Acknowledgements
We thank Mrs. Ulrike Ehlert for her skillful technical assistance. This work was supported by the German Federal Ministry of Education and Research (BMBF), grant no. 03/4507 (InnoRegio Health Region Berlin-Buch-Pharmacogenomic optimization of drug therapy and drug development) given to Cenimed GmbH, Center for Individualized Medicine, Berlin.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gerloff, T., Schaefer, M., Mwinyi, J. et al. Influence of the SLCO1B1*1b and *5 haplotypes on pravastatin’s cholesterol lowering capabilities and basal sterol serum levels. Naunyn Schmied Arch Pharmacol 373, 45–50 (2006). https://doi.org/10.1007/s00210-006-0053-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-006-0053-6